0,1,2
Table 6.6.1:  EAU risk groups for biochemical recurrence of localised and locally-advanced prostate,,
Recommendations,Strength rating,
"Offer bone protective agents to patients with mCRPC and skeletal metastases to prevent 
osseous complications.",Strong,
"Monitor serum calcium and offer calcium and vitamin D supplementation when prescribing 
either denosumab or bisphosphonates.",Strong,
"Treat painful bone metastases early on with palliative measures such as intensity-modulated 
radiation therapy/volumetric arc radiation therapy plus image-guided radiation therapy and 
adequate use of analgesics.",Strong,
"In patients with spinal cord compression start immediate high-dose corticosteroids and 
assess for spinal surgery followed by irradiation. Offer radiation therapy alone if surgery is 
not appropriate.",Strong,
Definition,,
"Low-risk
Intermediate-risk
High-risk",,
"any PSA
PSA > 20 ng/mL 
PSA 10â€“20 ng/mL 
PSA < 10 ng/mL 
any GS (any ISUP grade)*
Or GS > 7 (ISUP grade 4/5)
or GS 7 (ISUP grade 2/3)
and GS < 7 (ISUP grade 1) 
cT3-4* or cN+**
or cT2c*
or cT2b*
and cT1-2a*",,
"Localised
Locally advanced",,
Recommendations,Strength rating,
"No active treatment modality has shown superiority over any other active management 
options or deferred active treatment in terms of overall- and PCa-specific survival for 
clinically localised low/intermediate-risk disease.",Strong,
"Offer a watchful waiting policy to asymptomatic patients with clinically localised disease 
and with a life expectancy < 10 years (based on co-morbidities and age).",Strong,
Inform patients that all local treatments have side effects.,Strong,
Surgical treatment,,
"Radical prostatectomy can be safely delayed for at least 3 months from diagnosis in any 
risk category.",Weak,
"Inform patients that no surgical approach (open-, laparoscopic- or robotic radical 
prostatectomy) has clearly shown superiority in terms of functional or oncological results.",Weak,
"When a lymph node dissection (LND) is deemed necessary based on a nomogram, perform an 
extended LND template for optimal staging.",Strong,
"Consider avoiding nerve-sparing surgery when there is a risk of ipsilateral extra-capsular 
extension (based on cT stage, ISUP grade, magnetic resonance imaging, or with this 
information combined in a nomogram).",Weak,
Do not offer neoadjuvant androgen deprivation therapy before surgery.,Strong,
Radiotherapeutic treatment,,
"Offer intensity-modulated radiation therapy (IMRT) or volumetric arc radiation therapy 
(VMAT) plus image-guided radiation therapy (IGRT) for definitive treatment of PCa by 
external-beam radiation therapy.",Strong,
"Offer moderate hypofractionation (HFX) with IMRT/VMAT plus IGRT to the prostate to 
patients with localised disease (60 Gy/20 fractions in 4 weeks or 70 Gy/28 fractions in  
6 weeks).",Strong,
"Offer low-dose rate (LDR) brachytherapy monotherapy to patients with good urinary 
function and low-risk or NCCN favourable intermediate-risk disease.",Strong,
"Offer LDR or high-dose rate (HDR) brachytherapy boost combined with IMRT/VMAT plus 
IGRT to patients with good urinary function and NCCN unfavourable intermediate-risk or 
high-risk disease and/or locally-advanced disease.",Weak,
Active therapeutic options outside surgery or radiotherapy,,
"Only offer focal therapy with high-intensity focused ultrasound or cryotherapy within a 
Strong
clinical trial or prospective registry.",,
"Recommendations
Strength rating",,
Low-risk disease,,
"Watchful Waiting 
(WW)","Offer WW to patients with a life expectancy < 10 years.
Strong",
"Active 
surveillance (AS)","Manage patients with a life expectancy > 10 years and low-risk 
Strong
disease by AS.",
,Selection of patients,
,"Patients with intraductal histology on biopsy should be excluded from 
AS.",Strong
,"Perform magnetic resonance imaging (MRI) before a confirmatory 
biopsy if no MRI has been performed before the initial biopsy.",Strong
,"Take both targeted biopsy (of any PI-RADS > 3 lesion) and systematic 
biopsy if a confirmatory biopsy is performed.",Weak
,"If MRI is not available, per-protocol confirmatory prostate biopsies 
should be performed.",Weak
,"If a patient has had upfront MRI followed by systematic and targeted 
biopsies there is no need for confirmatory biopsies.",Weak
